Annexon Biosciences GAAP EPS of -$0.25 (ANNX:NASDAQ)
Annexon Biosciences (ANNX) reported a Q3 GAAP EPS of -$0.25. The company has $213 million in cash and short-term investments, expected to last into 2028. Annexon also discussed its vonaprument Phase III ARCHER II trial and plans for a Q4 BLA filing for tanruprubart.
How this was made
The 30-second read
Why it matters
The loss and cash balance suggest near‑term financial pressure, but the extended runway may support ongoing R&D.
Market read
Earnings miss for a micro‑cap biotech, likely prompting short‑term price decline.
What to watch
Potential upcoming Phase III data and partnership announcements could offset short‑term earnings disappointment.
Background
Annexon Biosciences is a NASDAQ‑listed biotech focused on ocular disease therapies. The Q3 release includes trial updates and cash position.
Ticker impact
Annexon Biosciences reported Q3 2026 GAAP EPS of -$0.25 and cash of $213 million, indicating a loss and runway into 2028.
likely downward pressure as investors price in the loss and modest cash position
The negative EPS and lack of revenue guidance suggest weaker performance than expectations, which typically triggers sell pressure in micro‑cap biotech stocks.
Market effects
Biotech sector may see slight pullback as earnings miss adds to sector risk sentiment.
US biotech micro‑caps could face broader weakness in after‑hours trading.
Limited; impact confined to niche biotech investors.
Counterpoint
If the cash runway to 2028 is viewed as sufficient for upcoming trial milestones, the stock could be undervalued despite the loss.
Key entities
- companyAnnexon Biosciences
NASDAQ‑listed biotech (ticker ANNX) reporting Q3 earnings.


